Compass Group’s fair value estimate has been trimmed slightly from $38.60 to about $38.50, a move of roughly 0.3% that ...

Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares fell 23% to $3.85 in premarket ...

Third Avenue Small-Cap Value Fund initiated a position in Compass, Inc. following its merger with Anywhere. Read the full ...

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

Compass Mining, a leading provider of Bitcoin mining infrastructure and services, today announced its new partnership with SpiderPool, the world's ...

Investing.com -- Compass Therapeutics (NASDAQ:CMPX) shares tumbled 80% Monday following mixed results from its Phase II/III COMPANION-002 trial evaluating tovecimig combined with paclitaxel in ...

Heartland Christian School will host Compass Career Day on Tuesday, featuring representatives from multiple businesses and ...

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...

Investing.com -- Compass Therapeutics, Inc. (NASDAQ:CMPX) shares fell 80% Monday after the company announced results from its COMPANION-002 Phase 2/3 study of tovecimig in biliary tract cancer ...

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...